switching between glp-1 agonists chart Glucagon-like peptide-1 receptor and risk of suicidality among patients with type 2 diabetes: active comparator, new user cohort study Glucagon-like peptide-1 receptor: mechanisms and
Description
We used version 2 of the Cochrane risk-of-bias tool for randomised trials to assess risk of bias for the primary outcome

GLP-1 receptor agonists (GLP-1 RAs) with exenatide b.i.d

Discover Weight Loss GLP-1 Tablets with Orforglipron in India

Five clinical trials in type 2-diabetic subjects (SURPASS 15) have shown that tirzepatide at 515 mg per week reduces both HbA1c (1.24 to 2.58%) and body weight (5.411.7 kg) by amounts unprecedented for a single agent

As we await prospective data, clinical practice should consider the difference between abrupt stop vs gradual taper when counseling patients about expectations after therapy

Read more
